Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal PharmaInvestors Business Daily • 08/18/25
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patientsCNBC • 08/18/25
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)GlobeNewsWire • 08/18/25
Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.Barrons • 08/18/25
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for CompetitorsThe Motley Fool • 08/17/25
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines AheadSeeking Alpha • 08/16/25
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says AnalystBenzinga • 08/15/25
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?Zacks Investment Research • 08/15/25
Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/SGlobeNewsWire • 08/14/25